Key facts
- Alkermes' experimental drug showed improvements in wakefulness.
- The drug also reduced daytime sleepiness in patients with a form of narcolepsy.
- This development suggests a new class of medicines may help more patients than previously expected.
Alkermes has announced positive results from a clinical trial for an experimental drug aimed at treating a form of narcolepsy. The drug demonstrated an ability to improve wakefulness and decrease daytime sleepiness among participants. This outcome suggests that the novel class of medications to which this drug belongs could potentially benefit a broader patient base than initially projected.